BioAtla (NASDAQ:BCAB) Issues Quarterly Earnings Results

BioAtla (NASDAQ:BCAB – Get Free Report) released its earnings results on Monday. The company reported ($4.74) EPS for the quarter, topping the consensus estimate of ($7.00) by $2.26, FiscalAI reports. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $5.59 million.

BioAtla Stock Performance

Shares of BioAtla stock opened at $1.56 on Monday. The stock has a market capitalization of $2.60 million, a PE ratio of -0.06 and a beta of 0.53. BioAtla has a 52-week low of $1.07 and a 52-week high of $71.50. The company has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $4.46.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioAtla in a report on Monday, August 31st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $200.00.

Read Our Latest Report on BioAtla

BioAtla Company Profile

(Get Free Report)

BioAtla, Inc. was a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company used its Conditionally Active Biologics (CAB) platform to design antibody-based medicines intended to become active primarily within the tumor microenvironment, with the goal of improving treatment effectiveness while limiting effects on healthy tissue. BioAtla’s investigational pipeline included antibody-drug conjugates and immune-modulating therapies. Its lead programs included mecbotamab vedotin, an antibody-drug conjugate designed to target AXL, and ozuriftamab vedotin, an investigational therapy directed at ROR2.

Read More

Earnings History for BioAtla (NASDAQ:BCAB)

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.